4 news items
InflaRx Hosts R&D Event Highlighting the Promise of INF904
IFRX
5 Jun 24
candidates; our expectations regarding the size of the patient populations for, market opportunity for, coverage and reimbursement for, estimated
InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators
IFRX
21 May 24
for, market opportunity for, coverage and reimbursement for, estimated returns and return accruals for, and clinical utility of GOHIBIC (vilobelimab
InflaRx Reports First Quarter 2024 Financial Results and Provides Business Update
IFRX
8 May 24
for, market opportunity for, coverage and reimbursement for, estimated returns and return accruals for, and clinical utility of GOHIBIC (vilobelimab) in its
InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event
IFRX
24 Apr 24
populations for, market opportunity for, coverage and reimbursement for, estimated returns and return accruals for, and clinical utility of GOHIBIC
- Prev
- 1
- Next